Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.31 USD | -0.76% |
|
+2.34% | -62.36% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 3.13M 3.5M |
---|---|---|---|---|---|
Net income 2024 * | -7M -7.82M | Net income 2025 * | -10M -11.17M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.3
x | P/E ratio 2025 * |
-0.41
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.11% |
Latest transcript on Altamira Therapeutics
1 week | +2.34% | ||
Current month | +18.02% | ||
1 month | +1.55% | ||
3 months | -28.42% | ||
6 months | -51.66% | ||
Current year | -62.36% |
![Extreme 1.2001](/images/extremecours_fleche.png)
![Extreme 1.0501](/images/extremecours_fleche.png)
![Extreme 1.0501](/images/extremecours_fleche.png)
![Extreme 1.0501](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Thomas Meyer
CEO | Chief Executive Officer | 56 | 03-03-31 |
Marcel Gremaud
DFI | Director of Finance/CFO | 66 | 21-10-31 |
Covadonga Pañeda
COO | Chief Operating Officer | 51 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Alain Munoz
BRD | Director/Board Member | 75 | 18-02-28 |
Mats Blom
BRD | Director/Board Member | 59 | 17-03-31 |
Thomas Meyer
CEO | Chief Executive Officer | 56 | 03-03-31 |
Date | Price | Change |
---|---|---|
24-07-12 | 1.31 | -0.76% |
24-07-11 | 1.32 | +2.33% |
24-07-10 | 1.29 | +3.20% |
24-07-09 | 1.25 | +2.46% |
24-07-08 | 1.22 | -4.69% |
Delayed Quote Nasdaq, July 12, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- CYTO Stock
- CYTO Stock